Exodus Technology
Nanoparticle-based, Non-drug Solution for Targeted, Permanent Chronic Pain Relief
StartupExodus Technology is a Giv'at Shmuel-based startup in the Health Tech & Life Sciences sector, established in 2025. Nanoparticle-based, Non-drug Solution for Targeted, Permanent Chronic Pain Relief. The company has raised a total of $150K across 1 funding round, currently at the Pre-Seed stage. Exodus Technology was founded by Michael Zilbershlag. Key investors include Israel Innovation Authority . The company has 1-10 employees. Core technologies: Materials & Substances, Nanomaterials, Biologicals.
With $150K in total funding, Exodus Technology is a Pre-Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B2C/B2B business model. Product stage: R&D. The company holds 1 patent.
- StagePre-Seed
- ProductR&D
- ModelB2B2C, B2B
- Employees1-10
- HQGiv'at Shmuel
- DistrictCenter District
- Last Round$150K
- Israel Innovation Authority
Michael ZilbershlagCEO
What does Exodus Technology do?
Nano Painkiller offers Focus Pain Ablation (FPA) technology as a groundbreaking, non-drug solution for targeted, permanent chronic pain relief. This innovation addresses the massive global health and economic burden of chronic pain, which affects approximately 20% of the adult Western population and fuels a global drug market valued at $78.41 billion in 2022. The critical need for alternatives stems from the opioid crisis, which has resulted in addiction, overdoses, and deaths, highlighting the failures and risks of current systemic drug therapies. The core technology uses a molecule comprising Gold Nanoparticles (AuNP), conjugated with a neuronal tracer. This molecule is injected into the painful area and transported retrogradely along the nerve axon to the sensory nerve cell body located in the Dorsal Root Ganglion (DRG). External Ultrasound (US) energy is then applied to the DRG to activate the nanoparticles, causing localized destruction of the specific cell body and silencing the pain signal. This two-stage selectivity ensures that motor nerves are not affected. The primary business opportunity lies in replacing repeat-intensive procedures and long-term drug dependence with a permanent solution. The initial application targets Knee Osteoarthritis Pain, a condition affecting 300 million people worldwide and valued at $6.76 billion. Compared to current Radiofrequency Ablation (RFA), FPA offers a longer-lasting effect because ablating the DRG cell body prevents nerve regrowth, thereby eliminating the need for repeating treatment every 3–6 months.
How much funding has Exodus Technology raised?
Exodus Technology has raised $150K in total funding across 1 rounds. The company is currently at the Pre-Seed stage. Key investors include Israel Innovation Authority .
Who founded Exodus Technology?
Exodus Technology was founded in 2025 by Michael Zilbershlag (CEO).
What sector is Exodus Technology in?
Exodus Technology operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Nanomaterials, Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Patients, Providers.
Where is Exodus Technology located?
Exodus Technology is based in Harimon St 4, Giv'at Shmuel, Israel, Center District.